BioDelivery Sciences to Present at Two Upcoming Investor Conferences
May 29, 2020 12:17 ET
|
BioDelivery Sciences International
RALEIGH, N.C., May 29, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...
BioDelivery Sciences Appoints Jeff Bailey Interim CEO
May 11, 2020 08:30 ET
|
BioDelivery Sciences International
RALEIGH, N.C., May 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...
BioDelivery Sciences Reports Strong Q1 2020 Results
May 07, 2020 16:01 ET
|
BioDelivery Sciences International
First Quarter Total Company Net Sales Increased 94% versus Prior Year to $38.3 Million First Quarter BELBUCA® Net Sales Increased 79% versus Prior Year to $33.5 Million Conference Call and...
BioDelivery Sciences to Report First Quarter 2020 Financial Results on May 7, 2020
April 28, 2020 08:00 ET
|
BioDelivery Sciences International
RALEIGH, N.C., April 28, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences Reports Strong Fourth Quarter and Full-Year 2019 Results
March 12, 2020 16:01 ET
|
BioDelivery Sciences International
Full-Year Total Company Net Sales Increased 100% versus Prior Year to $111.4 Million Full-Year BELBUCA® Net Sales Increased 112% versus Prior Year to $97.5 Million Fourth Quarter Total Company Net...
BioDelivery Sciences Appoints Jeffrey A. Bailey to its Board of Directors
March 09, 2020 08:00 ET
|
BioDelivery Sciences International
RALEIGH, N.C., March 09, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences Announces Phase I Clinical Trial Results at the American Academy of Pain Medicine’s 36th Annual Meeting
February 27, 2020 17:15 ET
|
BioDelivery Sciences International
BELBUCA® Effect on Respiratory Drive was Comparable to Placebo in Clinical Trial at all Tested Doses Immediate Release Oral Oxycodone HCl Associated with a Dose-Dependent Decrease in Respiratory...
BioDelivery Sciences to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
February 20, 2020 08:00 ET
|
BioDelivery Sciences International
RALEIGH, N.C., Feb. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...
BDSI Expects Fourth Quarter and 2019 Total Net Sales at the High End of Guidance: Reports Significantly Expanded Insurance Access for Symproic
January 13, 2020 08:30 ET
|
BioDelivery Sciences International
2019 Total Company Net Sales Expected at Upper End of $105 to $110 Million More than 25 Million Additional Lives Moved to Preferred Coverage for Symproic® effective January 1, 2020 ...
BioDelivery Sciences Appoints Kevin Ostrander as Senior Vice President of Business Development
January 06, 2020 08:30 ET
|
BioDelivery Sciences International
RALEIGH, N.C., Jan. 06, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...